Literature DB >> 11158754

Reduction of no synthase expression and tumor necrosis factor alpha production in macrophages by amphotericin B lipid carriers.

M Larabi1, P Legrand, M Appel, S Gil, M Lepoivre, J Devissaguet, F Puisieux, G Barratt.   

Abstract

The present study compared the abilities of different lipid carriers of amphotericin B (AMB) to activate murine peritoneal macrophages, as assessed by their capacities to produce nitric oxide (NO) and tumor necrosis factor alpha (TNF-alpha). Although AMB alone did not induce NO production, synergy was observed with gamma interferon but not with lipopolysaccharide. This synergy could not be explained by the mobilization of the nuclear activation factor NF-kappaB by AMB. On the other hand, AMB induced TNF-alpha production without a costimulator and no synergy was observed. Anti-TNF-alpha antibodies did not influence NO production, and an inhibitor of NO synthase did not affect TNF-alpha production, indicating that the production of one of these effector molecules was independent of that of the other. The incorporation of AMB into lipid carriers reduced NO and TNF-alpha production with all formulations but more so with liposomes than with lipid complexes. NO production was correlated with the induction of NO synthase II, revealed by Western blotting. The extent of association of AMB with macrophages depended on the formulation, especially on the AMB/lipids ratio: the higher the ratio was, the greater the AMB association with macrophages. However, there was no clear correlation between AMB association with macrophages, whether internalized or bound to the membrane, and immunostimulating effects. These results may explain the reduced toxicities of lipid-based formulations of AMB.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11158754      PMCID: PMC90326          DOI: 10.1128/AAC.45.2.553-562.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  52 in total

1.  Intravenous administration of amphotericin B entrapped in liposomes: induction of high serum levels of TNF alpha.

Authors:  J P Sculier; J J Body
Journal:  Ann Oncol       Date:  1991-02       Impact factor: 32.976

2.  Enhancement of macrophage superoxide anion production by amphotericin B.

Authors:  E Wilson; L Thorson; D P Speert
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

3.  Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action.

Authors:  F Dromer; J Charreire
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 5.226

4.  Leishmania major amastigotes initiate the L-arginine-dependent killing mechanism in IFN-gamma-stimulated macrophages by induction of tumor necrosis factor-alpha.

Authors:  S J Green; R M Crawford; J T Hockmeyer; M S Meltzer; C A Nacy
Journal:  J Immunol       Date:  1990-12-15       Impact factor: 5.422

5.  In vivo activation of macrophage oxidative burst activity by cytokines and amphotericin B.

Authors:  J E Wolf; S E Massof
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

6.  Tumour necrosis factor (TNF-alpha) in leishmaniasis. II. TNF-alpha-induced macrophage leishmanicidal activity is mediated by nitric oxide from L-arginine.

Authors:  F Y Liew; Y Li; S Millott
Journal:  Immunology       Date:  1990-12       Impact factor: 7.397

7.  Miconazole and amphotericin B alter polymorphonuclear leukocyte functions and membrane fluidity in similar fashions.

Authors:  K Yasui; M Masuda; T Matsuoka; M Yamazaki; A Komiyama; T Akabane; K Murata
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

8.  Sensitivity to tumour necrosis factor-mediated cytolysis is unrelated to manganous superoxide dismutase messenger RNA levels among transformed mouse fibroblasts.

Authors:  J M Boss; S M Laster; L R Gooding
Journal:  Immunology       Date:  1991-07       Impact factor: 7.397

9.  In-vitro effects of liposome-encapsulated amphotericin B (AmBisome) and amphotericin B-deoxycholate (Fungizone) on the phagocytic and candidacidal function of human polymorphonuclear leucocytes.

Authors:  C J Pallister; E M Johnson; D W Warnock; P J Elliot; D F Reeves
Journal:  J Antimicrob Chemother       Date:  1992-09       Impact factor: 5.790

10.  Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells.

Authors:  J D Cleary; S W Chapman; R L Nolan
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

View more
  6 in total

1.  Real-time reverse transcription-PCR quantification of cytokine mRNA expression in golden Syrian hamster infected with Leishmania infantum and treated with a new amphotericin B formulation.

Authors:  S Rama Iñiguez; M A Dea-Ayuela; J A Sanchez-Brunete; J J Torrado; J M Alunda; F Bolas-Fernández
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

2.  Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B.

Authors:  Malika Larabi; Vanessa Yardley; Philippe M Loiseau; Martine Appel; Philippe Legrand; Annette Gulik; Christian Bories; Simon L Croft; Gillian Barratt
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

3.  A curative immune profile one week after treatment of Indian kala-azar patients predicts success with a short-course liposomal amphotericin B therapy.

Authors:  Smriti Mondal; Pradyot Bhattacharya; Mehebubar Rahaman; Nahid Ali; Rama Prosad Goswami
Journal:  PLoS Negl Trop Dis       Date:  2010-07-27

4.  Antiproliferative Properties of Type I and Type II Interferon.

Authors:  Joseph Bekisz; Samuel Baron; Corey Balinsky; Angel Morrow; Kathryn C Zoon
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-30

Review 5.  Optimizing efficacy of Amphotericin B through nanomodification.

Authors:  Gillian Barratt; Stéphane Bretagne
Journal:  Int J Nanomedicine       Date:  2007

6.  Supplementation of host response by targeting nitric oxide to the macrophage cytosol is efficacious in the hamster model of visceral leishmaniasis and adds to efficacy of amphotericin B.

Authors:  Sanketkumar Pandya; Rahul Kumar Verma; Prashant Khare; Brajendra Tiwari; Dadi A Srinivasarao; Anuradha Dube; Neena Goyal; Amit Misra
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2016-01-14       Impact factor: 4.077

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.